Expert consensus document: A consensus on the medical treatment of acromegaly

Nature Reviews Endocrinology

Volumn 10, Issue 4, 2014, Pages 243-248

  Giustina, Andrea ^a   Chanson, Philippe ^b   Kleinberg, David ^c   Bronstein, Marcello D ^d   Clemmons, David R ^e   Klibanski, Anne ^f   Van Der Lely, Aart J ^g   Strasburger, Christian J ^h   Lamberts, Steven W ^g   Ho, Ken K Y ⁱ   Casanueva, Felipe F ^j   Melmed, Shlomo ^k  

^a UNIVERSITY OF BRESCIA   (Italy)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ PRINCESS ALEXANDRA HOSPITAL   (Australia)

^j UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^k CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; SOMATOMEDIN C; TEMOZOLOMIDE;

ACROMEGALY; COMORBIDITY; CONSENSUS; DRUG SAFETY; ENDOCRINE FUNCTION TEST; HUMAN; HYPOPHYSIS TUMOR; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; TUMOR REGRESSION; TUMOR VOLUME;

ACROMEGALY; CONSENSUS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PITUITARY NEOPLASMS; TREATMENT OUTCOME;

EID: 84897071723     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.21     Document Type: Review

References (75)

1. Melmed, S. et al. Consensus statement: medical management of acromegaly. Eur. J. Endocrinol. 153, 737-740 (2005).
2. Melmed, S. Acromegaly pathogenesis and treatment. J. Clin. Invest. 119, 3189-3202 (2009).
3. Giustina, A. et al. Current management practices for acromegaly: an international survey. Pituitary 14, 125-133 (2011).
4. Melmed, S. et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16, 294-302 (2013).
5. Melmed, S. et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509-1517 (2009).
6. Katznelson, L. et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update: executive summary. Endocr. Pract. 17, 636-646 (2011).
7. Melmed, S. Medical progress: acromegaly. N. Engl. J. Med. 355, 2558-2573 (2006).
8. Funder, J. W. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 3266-3281 (2008).
9. Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924-926 (2008).
10. Holdaway, I. M., Rajasoorya, R. C. & Gamble, G. D. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667-674 (2004).
11. Holdaway, I. M., Bolland, M. J. & Gamble, G. D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159, 89-95 (2008).
12. Clemmons, D. R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin. Chem. 57, 555-559 (2011).
13. Giustina, A. et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141-3148 (2010).
14. Carmichael, J. D., Bonert, V. S., Mirocha, J. M. & Melmed, S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J. Clin. Endocrinol. Metab. 94, 523-527 (2009).
15. Melmed, S. et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J. Clin. Endocrinol. Metab. 90, 4405-4410 (2005).
16. Mazziotti, G. & Giustina, A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13, 60-67 (2010).
17. Giustina, A. et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7, e36411 (2012).
18. Colao, A., Auriemma, R. S., Galdiero, M., Lombardi, G. & Pivonello, R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab. 94, 3746-3756 (2009).
19. Colao, A. et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin. Endocrinol. (Oxf.) 70, 757-768 (2009).
20. Ben-Shlomo, A., Sheppard, M. C., Stephens, J. M., Pulgar, S. & Melmed, S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14, 284-294 (2011).
21. Davi, M. V. et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur. J. Endocrinol. 159, 533-540 (2008).
22. Espinosa-de-los-Monteros, A. L., Gonzalez, B., Vargas, G., Sosa, E. & Mercado, M. Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 14, 231-235 (2011).
23. Bonadonna, S. et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Miner. Res. 20, 1837-1844 (2005).
24. Salvatori, R. et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary 13, 115-122 (2010).
25. Yang, L. P. & Keating, G. M. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 70, 1745-1769 (2010).
26. Toledano, Y. et al. Efficacy of long-term lanreotide treatment in patients with acromegaly. Pituitary 12, 285-293 (2009).
27. Schopohl, J. et al. Efficacy and acceptability of lanreotide Autogel120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp. Clin. Endocrinol. Diabetes 119, 156-162 (2011).
28. Murray, R. D. & Melmed, S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J. Clin. Endocrinol. Metab. 93, 2957-2968 (2008).
29. Petersenn, S. et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J. Clin. Endocrinol. Metab. 95, 2781-2789 (2010).
30. Tuvia, S. et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J. Clin. Endocrinol. Metab. 97, 2362-2369 (2012).
31. Sandret, L., Maison, P. & Chanson, P. Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327-1335 (2011).
32. Maione, L. et al. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J. Clin. Endocrinol. Metab. 97, E1714-E1719 (2012).
33. van der Lely, A. J. et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab. 97, 1589-1597 (2012).
34. Bonert, V. S. et al. Lipodystrophy in patients with acromegaly receiving pegvisomant. J. Clin. Endocrinol. Metab. 93, 3515-3518 (2008).
35. Garcia Basavilbaso, N. et al. Experience from the Argentine Pegvisomant Observational Study: preliminary data. Front. Horm. Res. 38, 42-49 (2010).
36. Sievers, C. et al. Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). Clin. Endocrinol. (Oxf.) 73, 89-94 (2010).
37. Trainer, P. J., Ezzat, S., DSouza, G. A., Layton, G. & Strasburger, C. J. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin. Endocrinol. (Oxf.) 71, 549-557 (2009).
38. Dekkers, O. M., Biermasz, N. R., Pereira, A. M., Romijn, J. A. & Vandenbroucke, J. P. Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 93, 61-67 (2008).
39. Burgers, A. M. et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. J. Clin. Endocrinol. Metab. 96, 2912-2920 (2011).
40. Colao, A. et al. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J. Clin. Endocrinol. Metab. 93, 2243-2248 (2008).
41. Gouya, H. et al. Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. AJR Am. J. Roentgenol. 190, 1576-1582 (2008).
42. Annamalai, A. K. et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J. Clin. Endocrinol. Metab. 98, 1040-1050 (2013).
43. Attal, P. & Chanson, P. Endocrine aspects of obstructive sleep apnea. J. Clin. Endocrinol. Metab. 95, 483-495 (2010).
44. Berg, C. et al. Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly. Eur. J. Endocrinol. 161, 829-835 (2009).
45. Biermasz, N. R. et al. Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. Eur. J. Endocrinol. 166, 407-413 (2012).
46. Claessen, K. M. et al. Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. Pituitary 17, 44-52 (2014).
47. Mazziotti, G. et al. Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93, 4649-4655 (2008).
48. Battista, C. et al. Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study. Clin. Endocrinol. (Oxf.) 70, 378-382 (2009).
49. Mazziotti, G. et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94, 1500-1508 (2009).
50. Roset, M. et al. Cost of clinical management of acromegaly in Spain. Clin. Drug Investig. 32, 235-245 (2012).
51. Sesmilo, G. et al. Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary 16, 115-121 (2013).
52. Bex, M. et al. AcroBel-the Belgian registry on acromegaly: a survey of the real-life outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 399-409 (2007).
53. Bevan, J. S. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab. 90, 1856-1863 (2005).
54. van der Lely, A. J. et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J. Clin. Endocrinol. Metab. 86, 478-481 (2001).
55. Jimenez, C. et al. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur. J. Endocrinol. 159, 517-523 (2008).
56. Buhk, J. H. et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J. Clin. Endocrinol. Metab. 95, 552-558 (2010).
57. Marazuela, M. et al. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J. Clin. Endocrinol. Metab. 96, E251-E259 (2011).
58. Carlsen, S. M. et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin. Endocrinol. (Oxf.) 74, 736-743 (2011).
59. Mao, Z. G. et al. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur. J. Endocrinol. 162, 661-666 (2010).
60. Shen, M. et al. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr. J. 57, 1035-1044 (2010).
61. Pita-Gutierrez, F. et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS ONE 8, e61523 (2013).
62. Trainer, P. J. ACROSTUDY: the first 5 years. Eur. J. Endocrinol. 161 (Suppl. 1), S19-S24 (2009).
63. Higham, C. E., Chung, T. T., Lawrance, J., Drake, W. M. & Trainer, P. J. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin. Endocrinol. (Oxf.) 71, 86-91 (2009).
64. Neggers, S. J. & van der Lely, A. J. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm. IGF Res. 21, 129-133 (2011).
65. Giustina, A. et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol. 161, 331-338 (2009).
66. Mazziotti, G. et al. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur. J. Endocrinol. 164, 341-347 (2011).
67. Fleseriu, M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 14, 184-193 (2011).
68. Auriemma, R. S. et al. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. Eur. J. Endocrinol. 162, 993-999 (2010).
69. Ozbek, M., Erdogan, M., Akbal, E. & Gonulalan, G. Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration. Exp. Clin. Endocrinol. Diabetes 117, 309-311 (2009).
70. Ramirez, C. et al. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur. J. Endocrinol. 166, 21-26 (2012).
71. Ronchi, C. L. et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur. J. Endocrinol. 158, 19-25 (2008).
72. Colao, A. et al. Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, phase III study. Endocrine Abstr. 29, OC1.1 (2012).
73. Somm, E. et al. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J. Clin. Invest. 122, 3295-3306 (2012).
74. Morin, E., Berthelet, F., Weisnagel, J., Bidlingmaier, M. & Serri, O. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 15, 97-100 (2012).
75. Hagen, C., Schroeder, H. D., Hansen, S., Hagen, C. & Andersen, M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur. J. Endocrinol. 161, 631-637 (2009).